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Background: The study of immune surveillance in the tumour microenvironment is leading to the 
development of new biomarkers and therapies. The present research focuses on the expression of CD5 
and CD6—two lymphocyte surface markers involved in the fine tuning of TCR signaling—as potential 
prognostic biomarkers in resectable stages of non-small cell lung cancer (NSCLC).
Methods: CD5 and CD6 gene expression was analysed by reverse transcription quantitative polymerase 
chain reaction (RTqPCR) in 186 paired fresh frozen tumour and normal tissue samples of resected NSCLC.
Results: Patients with higher CD5 expression had significantly increased overall survival (OS, 49.63 vs. 
99.90 months, P=0.013). CD5 expression levels were correlated to CD4 infiltration and expression levels, and 
survival analysis showed that patients with a higher CD5/CD4+ ratio had significantly improved prognosis. 
Multivariate analysis established CD5 expression as an independent prognostic biomarker for OS in early 
stages of NSCLC (HR=0.554; 95% CI, 0.360–0.853; P=0.007). Further survival analysis of NSCLC cases 
(n=97) from The Cancer Genome Atlas (TCGA) database, confirmed the prognostic value of both CD5 and 
CD6 expression¸ although CD6 expression alone did not reach significant prognostic value in our NSCLC 
training cohort.
Conclusions: Our data support further studies on CD5 and CD6 as novel prognostic markers in resectable 
NSCLC and other cancer types (i.e., melanoma), as well as a role for these receptors in immune surveillance.
Keywords: CD5; CD6; immune checkpoint; melanoma; non-small cell lung cancer (NSCLC)
Submitted Sep 27, 2019. Accepted for publication Feb 28, 2020.
doi: 10.21037/tlcr-19-445 
View this article at: http://dx.doi.org/10.21037/tlcr-19-445 
1083
1075Translational Lung Cancer Research, Vol 9, No 4 August 2020
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2020;9(4):1074-1083 | http://dx.doi.org/10.21037/tlcr-19-445 
Introduction
The immune system’s natural ability to detect and eliminate 
malignant cells is currently considered the best weapon in 
the battle against cancer. The study of immune biomarkers 
is critical to diagnose, prevent and choose the appropriate 
immunotherapy strategy in cancer treatment. The presence, 
localization, and proportion of helper and especially 
cytotoxic T cells (CTLs) in tumour-infiltrating lymphocytes 
(TILs) from aggressive cancers such as non-small cell lung 
cancer (NSCLC) and melanoma has been associated with a 
favorable prognosis (1-3). In recent years, gene expression 
patterns and single nucleotide polymorphism studies have 
contributed to cancer prognosis (4). Particularly, inducible 
immunoregulatory genes like immune checkpoints blockers 
(CTLA-4 or PD-1) expressed in TILs, are among the 
most predictive biomarkers for cancer clinical outcome 
and targets for immunotherapy (5,6). Identification of new 
immune biomarkers is still needed to fully understand the 
mechanisms of immune evasion and facilitate subsequent 
development of novel immunotherapies.
The lymphocyte surface co-receptors CD5 and CD6 are 
immunomodulators involved in the development, activation, 
differentiation and survival of lymphocytes (7,8). They are 
encoded by homologous genes derived from duplication of 
a common ancestral gene (9), and both are constitutively 
expressed by all T cells and the small B1a cell subset. CD5 
and CD6 are signal-transducing receptors that physically 
associate with the T and B cell antigen-specific clonotypic 
receptor (TCR and BCR, respectively) at the centre of the 
immune synapse (10,11). The endogenous CD6 ligands 
involve CD166/ALCAM (12), Galectins 1 and 3 (13) and 
CD318 (14), all broadly distributed on immune, epithelial, 
mesenchymal and/or cancer cells. In contrast, the nature 
of the CD5 ligand/s is ill-defined because no reported 
candidate (CD72, IgVH framework region, gp200, gp150, 
gp40-80, CD5 itself and IL-6) has been firmly validated by 
independent groups (7,15). Based on monoclonal antibody 
in vitro data, CD5 and CD6 were initially considered co-
stimulatory molecules (7,8). However, analysis of CD5 and 
CD6 knockout mice unveiled their negative modulatory 
role for thymocyte (and B1a) activation and differentiation 
signals upon clonotypic receptor cross-linking (16-19). 
Interestingly, this immunomodulatory role occurs even 
in the absence of ligand interaction (20,21). This implies 
that lymphocyte function can be up- or down-regulated 
by CD5 and CD6 expression. Accordingly, anergic T and 
B cells show upregulated surface CD5 expression (22,23). 
CD5 and CD6 expression also parallels TCR/CD3 levels 
and is predictive of TCR avidity and survival of T cells 
(24-27). Moreover, regulation of CD5 expression by TCR 
engagement has been reported in peripheral T cells (28). 
Regarding antitumour responses, in situ regulation of CD5 
expression by CTLs is thought to adapt their sensitivity to 
intra-tumour peptide-major histocompatibility complex 
(p-MHC) levels (29). Indeed, CTL clones from lung cancer 
patients show that CD5 expression is inversely proportional 
to their anti-tumour cytolytic activity, preventing activation-
induced cell death (AICD) during T cell overactivation (29).
CD5 and CD6’s modulation of lymphocyte activation 
and survival supports the hypothesis that their overall 
intra-tumour expression levels alter the anti-tumour 
immune response and can be therefore used as prognosis 
biomarkers in cancer. Accordingly, this study investigated 
the prognostic value of CD5 and CD6 gene expression in a 
cohort of 186 patients with resectable NSCLC. The results 
show that high intra-tumour levels of both CD5 and CD6 
associate to better prognosis as measured by overall survival 
and relapse-free survival. This was validated in silico using 
NSCLC biopsy information from The Cancer Genome 
Atlas (TCGA) database.
Methods
NSCLC patient cohort and sample collection
The training cohort included 186 patients with resected 
and non-pretreated stage I to IIIA NSCLC from Consorcio 
Hospital General Universitario de Valencia. Between 2004 and 
2017, 186 fresh-frozen tumour and normal tissue samples 
were obtained from surgical resection and preserved in 
RNAlater® (Applied Biosystems, USA). Patients who had 
received neoadjuvant treatment and those with a follow-
up shorter than 1 month were excluded. This study abides 
by the Declaration of Helsinki (as revised in 2013) and was 
approved by the institutional review board. All patients had 
signed the informed consent prior to sample collection.
Real-time PCR analysis of NSCLC patients
RNA was isolated using TRI Reagent® (Sigma, USA) 
and retrotranscribed using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, USA) in 
a MasterCycler® thermocycler (Eppendorf, Germany) 
following the manufacturer’s instructions. CD3D, CD3E, 
CD4, CD5, CD6 and CD8 gene expression was analysed by 
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RTqPCR using Taqman® hydrolysis probes and Taqman® 
Gene Expression Master Mix (Applied Biosystems, USA) in 
a LightCycler 480 thermocycler (Roche, Switzerland).
Relative gene expression was calculated by Pfaffl formula, 
taking into consideration expression differences between 
normal and tumour tissue, as well as RTqPCR efficiencies 
of each TaqMan® assay. Reference gene expression 
corresponds to the geometric mean of ACTB, CDKN1B 
and GUSB, endogenous controls used after evaluation with 
GeNorm software (30,31).
Immunohistochemistry (IHC)
CD5 and CD6  relative gene expression data were 
normalized against CD4+ and CD8+ lymphocyte infiltration 
in NSCLC samples (n=60). To do so, CD4 and CD8 
expression was evaluated in 60 Formalin-Fixed Paraffin 
Embedded (FFPE) samples using a Dako Autostainer 
Link 48 and the Dako EnVisionTM FLEX detection 
system (Dako, Canada). After section drying and antigen 
dewaxing in a PT Link instrument, the endogenous 
peroxidase activity was quenched with peroxidase 
blocking reagent in the Autostainer Link 48 instrument. 
Immunostaining was carried out with Dako FLEX Ready 
to-Use format for CD4 (Clone 4B12, Dako) and CD8 
(Clone C8/144B, Dako). Briefly, a detection system 
chromogen (3,3'-diaminobenzidine, DAB) was used after 
primary antibody incubation, followed by washing and 
counterstaining of sections with hematoxylin, dehydration 
and mounting. CD4+ and CD8+ lymphocytes were 
counted in 10 high power fields (HPF) (magnification 
×400) for tumour areas. Negative controls and normal 
human tonsil positive control tissue were included. IHC 
staining quantification was performed by two independent 
evaluators.
TCGA database search for CD5 and CD6 mRNA 
expression levels in NSCLC biopsies
Online information available at TCGA database (https://
cancergenome.nih.gov/) for NSCLC patients was 
downloaded and used as independent validation cohorts. 
Patients with resected NSCLC and available gene 
expression data for CD5 and CD6 in normal and tumour 
tissue samples were selected (n=97). Patients who had 
received neoadjuvant treatment or with follow-up shorter 
than 1 month were excluded.
Statistical analyses
Relative gene expression was dichotomized using median 
as a cut-off value. Non-parametric tests were used for 
correlations between clinico-pathological and analytical 
variables. Survival analyses were performed considering 
relapse-free survival (RFS) and overall survival (OS). RFS 
spans from surgery to relapse or exitus dates, and OS from 
surgery to exitus dates, following the Response Evaluation 
Criteria in Solid Tumours (RECIST). For patients who 
neither relapsed nor died, the last recorded follow-
up was considered. Gene prognostic value was assessed 
using Kaplan-Meier curves (Log-rank test) and univariate 
Cox regression analyses, followed by a multivariate Cox 
regression analysis, using all significant variables to establish 
independent prognostic biomarkers. Statistical analyses 
were performed using the Statistical Package for Social 
Sciences (SPSS) 15.0 software (Chicago, USA), considering 
significant P<0.05.
Results
Analysis of CD5 and CD6 expression in NSCLC samples 
from training cohort
The NSCLC training cohort was composed of 186 patients 
(see Table S1 for demographic and clinicopathological data), 
mainly men (85.0%) and current or former smokers (88.7%). 
Histology was squamous cell carcinoma in 47.9% and 
adenocarcinoma in 41.4% of all cases. During the follow-
up (median 34.2 months), 85 patients relapsed (45.7%) and 
91 died (48.9%). Non-parametric tests were conducted to 
determine an association of relative gene expression with 
clinicopathological variables.
The survival analyses revealed that high CD5 expression 
had significant biomarker prognostic value for OS (OS, 
49.63 vs. 99.90 months, P=0.013). Furthermore, a statistical 
trend toward significant RFS was detected (RFS, 29.20 
vs. 44.30 months, P=0.076) (Table 1; Figure 1). In contrast, 
similar analyses did not provide significant results for CD6 
expression (Table 1). Multivariate Cox regression analysis 
revealed high CD5 expression as a potential prognostic 
biomarker for OS in resected NSCLC patients (HR=0.554; 
95% CI, 0.360–0.853; P=0.007) (Table 2).
CD5 and CD6 are constitutively expressed lymphocytic 
receptors, whose expression can be regulated during 
lymphocyte development and activation events (32,33). 
Thus, mRNA level correlation to lymphocyte infiltration 
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or to up-regulation in infiltrating lymphocytes was assessed. 
To this end, CD5 and CD6 gene expression was normalized 
to CD4+ and CD8+ lymphocyte infiltration by IHC, and the 
CD5/CD4+, CD5/CD8+, CD6/CD4+ and CD6/CD8+ ratios 
were calculated in 60 samples. Survival analysis indicated 
that patients with higher CD5/CD4+ ratios had significantly 
improved prognosis (RFS, 13.33 vs. 66.97 months, 
P=0.023; OS, 25.73 vs. 73.93 months, P=0.019) (Figure S1). 
Furthermore, a tendency for improved RFS and OS was 
observed for CD5/CD8+, CD6/CD4+ and CD6/CD8+ ratios 
Table 1 Survival analysis of CD5 and CD6 in NSCLC patients of training cohort. Cox univariate analyses were conducted with dichotomized 
relative expression of CD5 and CD6
Univariate analysis
RFS OS
HR 95% CI P value HR 95% CI P value
CD5 (high vs. low) 0.708 0.483–1.038 0.077 0.592 0.390–0.898 0.014*
CD6 (high vs. low) 0.997 0.680–1.460 0.986 0.929 0.614–1.404 0.725
*, P value <0.05. NSCLC, non-small cell lung cancer; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence 
interval. 
Table 2 Multivariate cox regression analysis in NSCLC patients of training cohort. Cox multivariate analysis was conducted with all significant 




HR 95% CI P value HR 95% CI P value
Stage (IIIA vs. IIA/IIB vs. IA/IB) 1.565 1.219–2.010 0.0004* 1.625 1.234–2.139 0.001*
KRAS mutational status (mutated vs. WT) 2.126 1.280–3.531 0.004* 2.054 1.134–3.723 0.018*
PS (1/2 vs. 0) 1.661 1.102–2.504 0.015* 1.800 1.148–2.823 0.010*
CD5 (high vs. low) 0.554 0.360–0.853 0.007*
*, P value <0.05. NSCLC, non-small cell lung cancer; RFS, relapse-free survival; OS, overall survival; PS, performance status; WT, wild-
type; HR, hazard ratio; CI, confidence interval. 
Figure 1 NSCLC survival curves according to CD5 relative expression. Kaplan-Meier survival curves for (A) RFS and (B) OS of CD5 
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(Table S2).
In order to confirm these results, relative CD5 and CD6 
expression using RTqPCR was normalized against CD4 and 
CD8 expression in 186 NSCLC patients from our training 
cohort. Survival analysis confirmed that higher CD5/CD4 
expression was associated to improved OS (OS, 49.80 vs. 
99.90 months, P=0.042) (Figure S1), but no significant 
results were obtained neither for the rest of the ratios nor 
for RFS (Table S3). Additionally, and taking into account 
that the Spearman’s test correlated CD5 and CD6 to CD3D 
and CD3E, the CD5/CD3D, CD5/CD3E, CD6/CD3D and 
CD6/CD3E ratios were evaluated but showed no significant 
association to prognosis (Table S3).
In silico analysis of CD5 and CD6 expression from NSCLC 
TCGA database
Online information of 97 NSCLC patients from the TCGA 
database was used as a validation cohort. Their median 
follow-up was 27.61 months, time in which 27 (32.1%) 
patients had relapsed and 46 (47.4%) were exitus. The 
statistical analysis confirmed that higher expression of both 
CD5 and CD6 improved prognosis in NSCLC patients, as it 
was associated with increased RFS (34.98 vs. 75.57 months, 
P=0.033; 25.31 vs. 75.57 months, P=0.020, respectively) 
and OS (40.49 vs. 77.97 months, P=0.038; 39.02 vs. 
77.97 months, P=0.034, respectively) (Table 3; Figure 2). 
Multivariate analysis did not provide significant results on 
account of the small sample size (n=97). In all, our data 
supports that higher CD5 expression in early-stage NSCLC 
patients associates to increased OS. Regarding CD6, the 
validation cohort indicates a NSCLC biomarker potential 
that should be explored further.
Discussion
T h e  p r e s e n c e  o f  i m m u n e  c e l l s  i n  t h e  t u m o u r 
microenvironment plays a key role in NSCLC and 
melanoma prognosis (34,35). Our work provides a 
prognostic value for intratumour CD5 and CD6 mRNA 
expression, two lymphocyte co-receptors involved in 
modulation of T (and B1a) cell development, activation, 
differentiation and survival (7,8). High CD5 expression 
associates to favourable prognosis in 186 fresh-frozen 
samples of a NSCLC training cohort, validated further with 
online data from the NSCLC TCGA database. The analysis 
of CD6 expression in NSCLC tumour samples reveals 
similar associations. Furthermore, CD5 and CD6 expression 
correlate to the number of CD4+ and CD8+ lymphocytes 
and these ratios indicate better prognosis. Importantly, 
better prognosis also correlates with CD5 overexpression by 
TILs.
In order to explore the prognostic potential of CD5 
and CD6 expression in other cancer types, melanoma 
information from the TCGA database was analyzed. As 
illustrated in Figure S2 , better survival rate (“alive” group) 
presented significantly higher CD5 and CD6 expression, 
together with other T cell (CD3, CD4, CD8) and B cell 
(CD19) markers. There was also a significant overall 
difference rate between the “alive” and “dead” groups 
regarding time to progression (TTP) and OS considering 
high vs. low CD5 (Figure S3A,B) or CD6 expression (Figure 
S3C,D).
In addition, patients with better survival and tumour 
regression (no tumour in last follow-up) showed higher 
CD5 and CD6 expression, but lower CD3, CD4, CD8, CD19 
levels (Figure S2B), in support of infiltrating lymphocytes 
over-expressing CD5 and CD6 with better prognosis in 
melanoma.
Tumour microenvironment genetics has identified 
inhibitory or stimulatory lymphocyte accessory molecules 
(e.g., PD-1/CD279, CTLA-4, LAG-3, TIM-3 and 4-1BB/
CD137) that can be regulated to modulate T-cell activation 
and survival. Interestingly, these biomarkers distinguish 
tumour-specific T cells from unrelated T cells in the 
tumour infiltrate (36,37). This is illustrated by PD-1—
Table 3 Survival analysis of CD5 and CD6 in NSCLC patients of TCGA database. Cox univariate analyses were conducted with dichotomized 
relative expression of CD5 and CD6
Variables
RFS OS
HR 95% CI P value HR 95% CI P value
CD5 (high vs. low) 0.542 0.306–0.960 0.036* 0.537 0.296–0.975 0.041*
CD6 (high vs. low) 0.513 0.289–0.911 0.023* 0.530 0.292–0.961 0.037*
*, P value <0.05. RFS, relapse-free survival; NSCLC, non-small cell lung cancer; OS, overall survival; HR, hazard ratio; CI, confidence 
interval. 
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an inhibitory receptor inducibly expressed on activated 
T cells—as a marker of the tumour-reactive CD8+ T cell 
fraction in melanoma tumours (37) and of high avidity 
CD8+ T cells specific for Melan-A (38) or neoantigens (39). 
PD-1 expression is related to TCR signal strength, and thus 
to the functional avidity of specific T cells, underlining the 
complex significance of PD-1 expression on tumour-specific 
T cells (38).
Similar to PD-1 and CTLA-4, the CD5 and CD6 co-
receptors act as negative regulators of T cell activation 
(8,40). CD5- and CD6-deficient thymocytes are hyper-
reactive to TCR/CD3 cross-linking (16,18). Surface CD5 
and CD6 expression is set in the thymus, and parallels TCR/
CD3, becoming predictive of TCR avidity (16,18,19,24,25). 
Thus, thymocytes binding self-peptide-MHC (self-pMHC) 
with high affinity consequently deliver strong TCR-
mediated activation signals, and express higher CD5 and 
CD6 surface levels to overcome negative selection. Surface 
CD5 and CD6 promote thymocyte survival by different 
mechanisms (25,41). Post-positively selected (peripheral) 
CD4+ and CD8+ T cells with high CD5/CD6 expression 
(CD5/6hi) respond to foreign peptides with increased 
activation and survival (42-44). In other words, T cells 
with TCRs of stronger avidity for self-pMHC dominate 
in responses to foreign antigens and accumulate in aging 
individuals, revealing that positive selection contributes 
to effective immunity (42). This would be in line with our 
finding that high intratumour CD5 (and CD6) expression 
correlates with better NSCLC and Melanoma prognosis. 
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Figure 2 NSCLC survival curves according to the expression status of CD5 and CD6 of TCGA database patients. Kaplan-Meier survival 
curves for RFS and OS of CD5 (A and B) CD6 (C and D) expression levels in NSCLC patients of TCGA database. NSCLC, non-small cell 
lung cancer; RFS, relapse-free survival; OS, overall survival.
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reflect infiltrating T cells with higher avidity for tumour 
antigens and more resistant to activation-induced cell 
death (29).
Self-pMHC contact modulates CD5 expression, survival 
and homeostatic proliferation of naïve T cells in the 
periphery (28,45) suggesting modulation of CD5 on TILs at 
the tumour site. Indeed, in situ CD5 expression adaptation 
to pMHC levels of TILs from a lung carcinoma patient has 
been reported (46). The decreased MHC class I expression, 
observed in tumour escape from CD8+ T-cell killing, 
would induce TILs down-modulation of CD5 to prevent 
tumour evasion. In line with this, CD5lo CTL clones from 
lung carcinoma patients displayed higher tumour-specific 
cytotoxicity than CD5hi clones and increased susceptibility 
to tumour-induced AICD (29). This is in agreement with 
CD5’s prevention of AICD by negatively regulating T-cell 
activation (47). Higher AICD susceptibility of CD5lo 
CTLs would explain the transient control of tumour 
growth observed in CD5-deficient mice challenged with 
melanoma (48). Our work demonstrates that protection of 
CD5-deficient T cells from AICD by adenoviral-mediated 
expression of soluble Fas-Fc results in reduced melanoma 
growth (48). The latter may reflect a therapeutic strategy 
for patients showing low intratumour CD5 mRNA levels. 
In contrast, potentiation of TILs efficiency in tumours with 
high CD5 expression should include CD5 and Fas-FasL 
blocking strategies. A necessary CD5 blockade is supported 
by improved anti-tumour responses in mice expressing the 
soluble human CD5 (shCD5) transgene or injected with 
recombinant shCD5 (49,50).
Recent IHC analyses in small series (n=30) of untreated 
advanced-stage NSCLC patients concluded that intra-
tumour high CD3+ and low CD5+ infiltrates associate 
to poor prognosis (51). Melanoma patient genetics has 
revealed that the hypofunctional CD5 haplotype (isoform 
Pro224-Ala471, a poor down-regulator of TCR/CD3-
mediated T-cell activation) associates to better survival (29).
This is the first study of CD6 expression in tumour-
resected samples from early-stage NSCLC patients. No 
significance has been obtained in our NSCLC training 
cohort, but higher CD6 expression correlates with improved 
RFS and OS in our analyses of NSCLC and melanoma 
TCGA data. There is little information on the function of 
CD6. However, the homology between CD5 and CD6, may 
enable some degree of functional redundancy. Knockout 
mice show that both receptors share modulatory roles 
in thymocyte activation (negative) and survival (positive) 
(16,18,19). Moreover, Nur-77 levels -indicative of TCR 
signaling strength- are elevated in CD6hi compared to 
CD6lo peripheral T cells (18). CD6lo/neg peripheral T cell 
populations are less responsive to T-cell activators, more 
susceptible to apoptosis and enriched in regulatory T cells 
(Treg) (27,52). High TCR avidity and survival of CD6hi 
T cells would be compatible with high intratumour CD6 
expression and favourable cancer prognosis, suggesting its 
biomarker potential only awaits confirmation.
In order to determine if CD5 expression association 
to favourable prognosis is due to higher lymphocyte 
infiltration, CD5 and CD6 ratios to CD4 and CD8 were 
calculated. Our results confirm their prognostic value 
and support that higher CD5 expression and lymphocyte 
infiltration associate to increased antitumour immune 
responses and improved patient prognosis in early-stage 
NSCLC.
Conclusions
This study points to a positive prognostic role for two 
lymphocyte inhibitory co-receptors, CD5 and CD6, in 
early-stage NSCLC (and in Melanoma). This conclusion 
is compatible with high surface levels of both CD5 and 
CD6 associated to TCR avidity and resistance to AICD. 
This evidence suggests that CD5 and CD6, along with 
other checkpoint inhibitors (e.g., PD-1 and CTLA-4), may 
be additional markers of tumour-specific T cells. Further 
studies deciphering the exact role of CD5, CD6 and their 
ligands in cancer would benefit patient stratification for 
personalized immunotherapies and development of new and 
more efficient strategies.
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Supplementary
Figure S1 NSCLC survival curves according to CD5 ratios. (A) Kaplan-Meier survival curve for RFS of CD5 relative expression normalized 
to CD4 infiltration (CD5/CD4+). (B) Kaplan-Meier survival curve for OS of CD5 relative expression normalized to CD4 infiltration (CD5/
CD4+). (C) Kaplan-Meier survival curve for OS of CD5/CD4 expression levels in NSCLC patients of the training cohort. NSCLC, non-








































































0          20          40          60          80         100         120 
0           25            50           75           100         125 
0          20          40          60          80         100         120 
Figure S2 Retrospective analysis of gene expression in human melanoma samples from TCGA database. (A) Melanoma tumor biopsies 
(n=409) were divided into “alive” [being alive for more than 4 years (1,460 days) from day of diagnosis; n=74, blue plot] or “dead” [being 
dead in less than 2 years (730 days) from diagnosis; n=49], black plot] groups. (B) The alive group was subdivided into two other groups; with 
tumor (information of last follow-up; n=16, black plot) and without tumor (information of last follow-up; n=58, blue plot). Gene expression 
values of CD3δ, CD3ε, CD4, CD8α, CD8β, CD19, CD6, CD5 and ALCAM are presented in both graphs. Mann-Whitney test was used for 
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Figure S3 Melanoma-specific survival curves according to the expression status of CD5 and CD6. Kaplan-Meier survival curves for time to 
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Table S1 Clinicopathological characteristics of patients included in NSCLC training 
Cohort
Characteristics N, n=186 %









































NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; ADC, 
adenocarcinoma; NS, not specified.
Table S2 Survival analysis of CD5 and CD6 ratios in NSCLC patients of training cohort. Cox univariate analyses were conducted with 
dichotomized relative expression of CD5 and CD6, normalized against CD4+ and CD8+ infiltration measured by IHC in a subset of 60 patients
Univariate analysis
RFS OS
HR 95% CI P value HR 95% CI P value
CD5/CD4+ (high vs. low) 0.428 0.202–0.907 0.027* 0.392 0.175–0.879 0.023*
CD5/CD8+ (high vs. low) 0.675 0.360–1.266 0.221 0.584 0.304–1.122 0.107
CD6/CD4+ (high vs. low) 0.644 0.309–1.342 0.240 0.580 0.265–1.268 0.172
CD6/CD8+ (high vs. low) 0.664 0.353–1.247 0.203 0.574 0.299–1.105 0.097
*, P value <0.05. NSCLC, non-small cell lung cancer; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence 
interval.
Table S3 Survival analysis of CD5 and CD6 ratios in NSCLC patients of training cohort. Cox univariate analyses were conducted with 




HR 95% CI P value HR 95% CI P value
CD5/CD3D (high vs. low) 1.010 0.687–1.485 0.958 0.859 0.567–1.301 0.473
CD5/CD3E (high vs. low) 0.925 0.631–1.357 0.691 0.846 0.559–1.281 0.430
CD5/CD4 (high vs. low) 0.906 0.617–1.330 0.613 0.633 0.406–0.988 0.044*
CD5/CD8 (high vs. low) 0.941 0.641–1.380 0.754 0.833 0.550–1.261 0.387
CD6/CD3D (high vs. low) 1.093 0.744–1.605 0.650 1.081 0.714–1.637 0.712
CD6/CD3E (high vs. low) 0.977 0.664–1.436 0.905 0.908 0.598–1.379 0.650
CD6/CD4 (high vs. low) 0.858 0.585–1.259 0.435 0.798 0.527–1.209 0.287
CD6/CD8 (high vs. low) 0.970 0.661–1.424 0.878 0.835 0.551–1.266 0.396
*, P value <0.05. NSCLC, non-small cell lung cancer; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence 
interval. 
